JUNE 18. 2020
Dr. Phyllis Holditch Niolon
Senior Scientist for ACES Prevention
Division of Violence Prevention Centers for Disease Control and Prevention (CDC)
Phyllis Holditch Niolon, PhD, is a behavioral scientist in the Division of Violence Prevention, National Center for Injury Prevention and Control. Dr. Niolon serves as a senior subject matter expert (SME) on Intimate Partner Violence (IPV) and Teen Dating Violence (TDV). In this role, she responds to high-level information requests from the legislative and executive branches of government and from the media relating to the topics of IPV and TDV. She is the lead author of the Division’s technical package on the prevention of IPV, Preventing Intimate Partner Violence Across the Lifespan: A Technical Package of Programs, Policies, and Practices, and has made numerous presentations on the package to a host of audiences since its publication. Since 2009, she has served as the lead of the randomized controlled trial evaluating the comparative effectiveness of CDC’s Dating Matters®: Strategies to Promote Healthy Teen Relationships Initiative. Dr. Niolon graduated with High Distinction with a Bachelor of Arts in Psychology from the University of Virginia. She received her masters and doctorate of philosophy in Community Psychology from Georgia State University. After serving as a postdoctoral fellow in the Division of Violence Prevention for one year, she joined DVP as a behavioral scientist in 2006. Since coming to CDC she has served as a science officer on numerous cooperative agreements and contracts evaluating interventions to prevent IPV and TDV. She has published multiple peer reviewed journal articles, book chapters and government documents on the topics of IPV and TDV.
Adverse Childhood Experiences: Impact on Communities
This workshop will discuss the Adverse Childhood Experiences (ACEs) and their connection to Addiction. We will explore what ACEs are, how they affect development, and how they increase risk for a host of physical, mental, and behavioral health outcomes, including substance misuse and overdose. We will discuss opportunities for prevention of ACEs, thereby preventing later outcomes. We will end with thoughts about how the current COVID-19 pandemic may be affecting ACEs and Addiction.